Previous 10 | Next 10 |
home / stock / esalf / esalf news
FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease TOKYO and CAMBRIDGE, Mass., June 10, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today tha...
2024-06-06 10:09:40 ET More on Eli Lilly Is It Possible Eli Lilly Is Breaking Out To New All-Time Highs? Eli Lilly and Company (LLY) Lilly Oncology ASCO Investor Event (Transcript) Eli Lilly's Growth And Challenges: A Cautious Buy Eli Lilly snaps six straight...
2024-06-05 13:10:12 ET More on Biogen, Eli Lilly, etc. Eli Lilly and Company (LLY) Lilly Oncology ASCO Investor Event (Transcript) Eli Lilly's Growth And Challenges: A Cautious Buy Eli Lilly: Addressing Supply Challenges Should Accelerate Growth Alphabet taps...
Eisai Named to List of The Time 100 Most Influential Companies TOKYO, June 3, 2024 - (JCN Newswire) - TIME reveals the TIME100 Most Influential Companies list, highlighting companies making an extraordinary impact around the world. To assemble the list, TIME solicited nominations ac...
Eisai Strengthens Venture Investment Business Aimed at Accelerating Drug Discovery Innovation and Establishment of Ecosystem Platform TOKYO, June 3, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company decided to strengthen and continue its venture investment bus...
2024-06-02 03:00:00 ET Summary Suzhou MediLink partners with BioNTech to use its antibody-drug conjugate platform, receiving an upfront payment of $25 million and up to $1.8 billion in milestones. Asahi Kasei offers $1.1 billion to acquire Calliditas Therapeutics, aiming to expand...
"LEQEMBI" Lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea TOKYO and CAMBRIDGE, Mass., May 28, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Food and Drug Safety (MFDS) in South Korea has approved humanized an...
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024 TOKYO, May 23, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society of Clinical Onco...
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Launched In Japan TOKYO, May 22, 2024 - (JCN Newswire) - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac group announced today that they have launched the anti-rheumatic agent "Metoject...
2024-05-16 21:14:05 ET Eisai Co Ltd. (ESALF) Q4 2024 Results Conference Call May 16, 2024 2:00 AM ET Company Participants Haruo Naito - CEO, Representative Corporate Officer & Director Keisuke Naito - SVP, Chief Strategy, Planning & Ecosystem Officer and Acti...
News, Short Squeeze, Breakout and More Instantly...
Eisai Co Ltd Company Name:
ESALF Stock Symbol:
OTCMKTS Market:
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC) TOKYO, July 2, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squi...
Eisai: "LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China TOKYO and CAMBRIDGE, Mass., June 28, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that the humanized anti-soluble aggregated amyloid-beta (Abeta) monoclo...
Eisai Continues Contract for FY2024 Dementia Examination Project by Tokyo Bunkyo City TOKYO, June 21, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company has achieved the pre-set performance indicators in FY2023 for the dementia examination project in Bunkyo Cit...